JNJ-26481585 Size:2mg solid PubMed PMID: 23907354

PubMed PMID: 23907354

pretreatment with SF-1670 also significantly augments PtdIns(3

Suplatast tosilate (100 mg/kg/100 μL) significantly reduces the number of total cells and eosinophils in BALF (around -40%) and almost completely inhibits the development of antigen-induced BHR

InChiKey: GXCGXOBFROXMLV-UHFFFAOYSA-N

JNJ-26481585 Size:2mg solid PubMed PMID: 23907354Quisinostat (USAN; development code JNJ 26481585) is an experimental drug candidate for the treatment of cancer. It is a "second generation" histone deacetylase inhibitor with antineoplastic activity. It is highly potent against class I and II HDACs. Product information CAS Number: 875320 29 9 Molecular Weight: 394. 47 Formula: C21H26N6O2 Synonym: Quisinostat Related CAS Number: 1083078 98 1 (Quisinostat hydrochloride) 875320 31 3 (Quisinostat